Ashton Thomas Private Wealth LLC Acquires 4,678 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Ashton Thomas Private Wealth LLC grew its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 106.7% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 9,062 shares of the medical equipment provider's stock after purchasing an additional 4,678 shares during the period. Ashton Thomas Private Wealth LLC's holdings in Zimmer Biomet were worth $959,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in ZBH. Callan Family Office LLC acquired a new position in Zimmer Biomet in the fourth quarter valued at about $1,153,000. E Fund Management Co. Ltd. boosted its holdings in shares of Zimmer Biomet by 74.6% in the 4th quarter. E Fund Management Co. Ltd. now owns 3,530 shares of the medical equipment provider's stock worth $373,000 after acquiring an additional 1,508 shares in the last quarter. Candriam S.C.A. grew its position in Zimmer Biomet by 24.9% during the 4th quarter. Candriam S.C.A. now owns 21,769 shares of the medical equipment provider's stock worth $2,299,000 after acquiring an additional 4,336 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in Zimmer Biomet during the 4th quarter valued at $21,234,000. Finally, Arizona State Retirement System raised its position in Zimmer Biomet by 0.4% in the 4th quarter. Arizona State Retirement System now owns 59,152 shares of the medical equipment provider's stock valued at $6,248,000 after purchasing an additional 211 shares during the last quarter. Institutional investors own 88.89% of the company's stock.

Insider Buying and Selling at Zimmer Biomet

In other news, SVP Lori Winkler sold 1,443 shares of the firm's stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total value of $150,649.20. Following the completion of the transaction, the senior vice president now owns 8,768 shares in the company, valued at $915,379.20. This trade represents a 14.13 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.95% of the company's stock.

Remove Ads

Analyst Ratings Changes

ZBH has been the subject of a number of research reports. Barclays lowered their target price on Zimmer Biomet from $118.00 to $112.00 and set an "underweight" rating for the company in a research note on Monday, February 10th. JPMorgan Chase & Co. upgraded shares of Zimmer Biomet from a "neutral" rating to an "overweight" rating and raised their price objective for the company from $125.00 to $128.00 in a research report on Tuesday, December 17th. Stifel Nicolaus upped their target price on shares of Zimmer Biomet from $130.00 to $138.00 and gave the stock a "buy" rating in a research report on Thursday, January 23rd. Truist Financial reissued a "hold" rating and issued a $113.00 price target (down previously from $118.00) on shares of Zimmer Biomet in a report on Monday, February 10th. Finally, Raymond James reduced their price objective on Zimmer Biomet from $126.00 to $119.00 and set an "outperform" rating on the stock in a report on Friday, February 7th. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, Zimmer Biomet has an average rating of "Hold" and an average price target of $124.15.

Zimmer Biomet Trading Up 3.5 %

Zimmer Biomet stock traded up $3.60 during mid-day trading on Thursday, hitting $107.63. 2,058,288 shares of the company's stock were exchanged, compared to its average volume of 1,921,787. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $97.69 and a fifty-two week high of $133.90. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43. The firm has a market capitalization of $21.43 billion, a P/E ratio of 24.19, a PEG ratio of 1.95 and a beta of 1.04. The company's 50 day simple moving average is $105.65 and its 200-day simple moving average is $107.05.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, topping analysts' consensus estimates of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same quarter last year, the company earned $2.20 EPS. On average, equities analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be issued a dividend of $0.24 per share. The ex-dividend date of this dividend is Monday, March 31st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.89%. Zimmer Biomet's payout ratio is presently 21.57%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.